All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche and sobi, and supported through educational grants from Bristol Myers Squibb, Incyte and Lilly. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lymphoma & CLL content recommended for you
Anna SuredaDuring ASCO 2019 held in Chicago, US, Anna M Sureda, Catalan Institute of Oncology, Barcelona, ES, spoke to the Lymphoma Hub about the sequencing of targeted therapies in patients with relapsed follicular lymphoma.
Dr. Sureda explains how most patients are not being cured with first-line chemotherapy and in daily clinical practice, physicians are faced with many difficult patients, that need additional treatment. Dr. Sureda explains that there are several types of targeted therapies that have given interesting results most of which are in phase II prospective clinical trials and some even in phase III prospective trials that have been able to improve the long term outcomes of patients, these include new anti-CD20 monoclonal antibodies, PA3K inhibitors, and antibody drug conjugates.
Sequencing of targeted therapies in relapsed follicular lymphoma
Your opinion matters
In your experience, when do most CRS/ICANS events occur after lisocabtagene maraleucel infusion?